ArticleBlood advances2026
A scalable high-throughput platform for the discovery of intracellular and extracellular regulators of platelet migration.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
abstractThe migration of platelets is increasingly recognized for its roles in inflammation, infection, and malignancy. Platelet migration has been found to be an αIIbβ3 integrin-dependent process that occurs on fibrinogen deposited at endothelial junctions, but other integrins and extracellular matrix (ECM) proteins may also support this behavior. Here, we present a novel imaging and analysis pipeline for quantifying platelet migration, combining an improved coating/blocking method with convolutional neural network-based automated segmentation and tracking to enable scalable, unbiased assessment of migration phenotypes. Using this high-throughput platform, we systematically investigated how ECM ligand availability, integrin subtype engagement (β1 vs β3), and pharmacological perturbation of motility pathways influence platelet migration. In addition to fibrinogen, platelet migration was observed on fibronectin and vitronectin, mediated by both αIIbβ3 and β1 integrins. Migrating platelets formed retraction fibers and left behind migrasomes, cell fragments with potentially proinflammatory/procoagulant activity. Platelet migration on fibrinogen was sensitive to inhibitors of the actomyosin cytoskeleton and was significantly impaired by high ligand concentrations, lack of the γ-chain AGDV motif, preincubation with agents blocking fibrinogen-αIIbβ3 interaction, or deficiency in key components of the integrin activation complex. In summary, establishment of a novel high-throughput assay facilitated in-depth studies of platelet migration mechanisms, with findings that highlight integrin-ligand interactions as potential therapeutic targets to limit platelet-driven inflammatory tissue damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.